Cargando…
Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience
Cutaneous metastasis (CM) occurs infrequently and usually presents during the later stages of cancer, and has a poor prognosis. Although there are insufficient current data, cancer treatment changes could have a positive impact on the outcome. This retrospective study aimed to review the pattern and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294925/ https://www.ncbi.nlm.nih.gov/pubmed/34398051 http://dx.doi.org/10.1097/MD.0000000000026737 |
_version_ | 1783725332134625280 |
---|---|
author | Teyateeti, Phurichaya Ungtrakul, Teerapat |
author_facet | Teyateeti, Phurichaya Ungtrakul, Teerapat |
author_sort | Teyateeti, Phurichaya |
collection | PubMed |
description | Cutaneous metastasis (CM) occurs infrequently and usually presents during the later stages of cancer, and has a poor prognosis. Although there are insufficient current data, cancer treatment changes could have a positive impact on the outcome. This retrospective study aimed to review the pattern and prognosis of CM in patients with solid malignancy in a tertiary cancer center in Thailand. We reviewed the medical records of cancer patients diagnosed with CM between October 2009 and August 2015 at Chulabhorn Hospital, a tertiary cancer center in Thailand. Patients with primary skin cancer and hematological malignancies were excluded. We collected and analyzed data, including the time of cancer diagnosis and CM, type of cancer, clinical characteristics, and survival outcome. Of 11,418 patients, there were 33 (0.3%) were diagnosed with CM. Breast cancer was the most common primary cancer (12 cases, 36%). Skin nodules were commonly detected on the anterior chest wall. Also, 79% of CM patients had concomitant visceral metastasis. The median overall survival of those with CM was 9.21 months (95% confidence interval 4.75–83.38 months) regardless of presentation either at onset or disease recurrence (P = .083). However, the change of management was affected in 78% diagnosed with a later stage of CM. No statistical difference in survival was observed between breast cancer and non-breast cancer patients (8.79 vs 9.21 months, P = .613). Despite CM being a sign of poor prognosis, it may still be an indicator for changing cancer patients’ treatment. Hence, early CM diagnosis and prompt novel therapy may positively affect outcomes for cancer patients. |
format | Online Article Text |
id | pubmed-8294925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-82949252021-07-24 Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience Teyateeti, Phurichaya Ungtrakul, Teerapat Medicine (Baltimore) 5700 Cutaneous metastasis (CM) occurs infrequently and usually presents during the later stages of cancer, and has a poor prognosis. Although there are insufficient current data, cancer treatment changes could have a positive impact on the outcome. This retrospective study aimed to review the pattern and prognosis of CM in patients with solid malignancy in a tertiary cancer center in Thailand. We reviewed the medical records of cancer patients diagnosed with CM between October 2009 and August 2015 at Chulabhorn Hospital, a tertiary cancer center in Thailand. Patients with primary skin cancer and hematological malignancies were excluded. We collected and analyzed data, including the time of cancer diagnosis and CM, type of cancer, clinical characteristics, and survival outcome. Of 11,418 patients, there were 33 (0.3%) were diagnosed with CM. Breast cancer was the most common primary cancer (12 cases, 36%). Skin nodules were commonly detected on the anterior chest wall. Also, 79% of CM patients had concomitant visceral metastasis. The median overall survival of those with CM was 9.21 months (95% confidence interval 4.75–83.38 months) regardless of presentation either at onset or disease recurrence (P = .083). However, the change of management was affected in 78% diagnosed with a later stage of CM. No statistical difference in survival was observed between breast cancer and non-breast cancer patients (8.79 vs 9.21 months, P = .613). Despite CM being a sign of poor prognosis, it may still be an indicator for changing cancer patients’ treatment. Hence, early CM diagnosis and prompt novel therapy may positively affect outcomes for cancer patients. Lippincott Williams & Wilkins 2021-07-23 /pmc/articles/PMC8294925/ /pubmed/34398051 http://dx.doi.org/10.1097/MD.0000000000026737 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 5700 Teyateeti, Phurichaya Ungtrakul, Teerapat Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience |
title | Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience |
title_full | Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience |
title_fullStr | Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience |
title_full_unstemmed | Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience |
title_short | Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience |
title_sort | retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: a tertiary cancer center experience |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294925/ https://www.ncbi.nlm.nih.gov/pubmed/34398051 http://dx.doi.org/10.1097/MD.0000000000026737 |
work_keys_str_mv | AT teyateetiphurichaya retrospectivereviewofcutaneousmetastasisamong11418patientswithsolidmalignancyatertiarycancercenterexperience AT ungtrakulteerapat retrospectivereviewofcutaneousmetastasisamong11418patientswithsolidmalignancyatertiarycancercenterexperience |